Freshwater T - Search Results

1

A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1-Related Plexiform Neurofibromas and Healthy Volunteers.

Zuo P, Arefayene M, Pan WJ, Freshwater T, Monteleone J. Zuo P, et al. Among authors: freshwater t. Clin Pharmacol Drug Dev. 2024 Apr 9. doi: 10.1002/cpdd.1400. Online ahead of print. Clin Pharmacol Drug Dev. 2024. PMID: 38591154

2

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.

Chénard-Poirier M, Hansen AR, Gutierrez ME, Rasco D, Xing Y, Chen LC, Zhou H, Webber AL, Freshwater T, Sharma MR. Chénard-Poirier M, et al. Among authors: freshwater t. Invest New Drugs. 2024 Mar 14. doi: 10.1007/s10637-024-01428-0. Online ahead of print. Invest New Drugs. 2024. PMID: 38483782

3

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Among authors: freshwater t. Invest New Drugs. 2024 Feb;42(1):145-159. doi: 10.1007/s10637-023-01410-2. Epub 2024 Feb 7. Invest New Drugs. 2024. PMID: 38324085 Clinical Trial.

4

A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.

Peribañez-Dominguez S, Parra-Guillen ZP, Freshwater T, Troconiz IF. Peribañez-Dominguez S, et al. Among authors: freshwater t. Front Pharmacol. 2023 Sep 13;14:1211452. doi: 10.3389/fphar.2023.1211452. eCollection 2023. Front Pharmacol. 2023. PMID: 37771727 Free PMC article.

5

Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling.

Parra-Guillen ZP, Sancho-Araiz A, Mayawala K, Zalba S, Garrido MJ, de Alwis D, Troconiz IF, Freshwater T. Parra-Guillen ZP, et al. Among authors: freshwater t. Clin Pharmacol Ther. 2023 Sep;114(3):623-632. doi: 10.1002/cpt.2937. Epub 2023 Jun 2. Clin Pharmacol Ther. 2023. PMID: 37170933

6

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Stathis A, Tolcher AW, Wang JS, Renouf DJ, Chen LC, Suttner LH, Freshwater T, Webber AL, Nayak T, Siu LL. Stathis A, et al. Among authors: freshwater t. Invest New Drugs. 2023 Jun;41(3):380-390. doi: 10.1007/s10637-022-01326-3. Epub 2023 Apr 11. Invest New Drugs. 2023. PMID: 37040046 Free PMC article. Clinical Trial.

7

Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration.

Parra-Guillen ZP, Freshwater T, Cao Y, Mayawala K, Zalba S, Garrido MJ, de Alwis D, Troconiz IF. Parra-Guillen ZP, et al. Among authors: freshwater t. Front Pharmacol. 2021 Jul 23;12:705443. doi: 10.3389/fphar.2021.705443. eCollection 2021. Front Pharmacol. 2021. PMID: 34366859 Free PMC article.

8

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.

Cohen-Rabbie S, Zhou L, Vishwanathan K, Wild M, Xu S, Freshwater T, Jain L, Schalkwijk S, Tomkinson H, Zhou D. Cohen-Rabbie S, et al. Among authors: freshwater t. J Clin Pharmacol. 2021 Nov;61(11):1493-1504. doi: 10.1002/jcph.1935. Epub 2021 Jul 22. J Clin Pharmacol. 2021. PMID: 34196005 Free PMC article.

9

Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.

Schalkwijk S, Zhou L, Cohen-Rabbie S, Jain L, Freshwater T, So K, He Z, Gioni I, Tomkinson H, Vishwanathan K, Zhou D. Schalkwijk S, et al. Among authors: freshwater t. Cancer Chemother Pharmacol. 2021 Aug;88(2):189-202. doi: 10.1007/s00280-021-04274-6. Epub 2021 Apr 26. Cancer Chemother Pharmacol. 2021. PMID: 33903938

10

Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology.

Li TR, Chatterjee M, Lala M, Abraham AK, Freshwater T, Jain L, Sinha V, de Alwis DP, Mayawala K. Li TR, et al. Among authors: freshwater t. Clin Pharmacol Ther. 2021 Jul;110(1):200-209. doi: 10.1002/cpt.2170. Epub 2021 Mar 8. Clin Pharmacol Ther. 2021. PMID: 33462831

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page